Journal of Innovations in Medical Research and Clinical case Reports (JIMRCR)

OLITES PUBLISHERS
A Global Approach For Research

Open Access

Mini Review

Primary Biliary Cholangitis: A Silent Autoimmune Assault on the Liver's Bile Ducts

*** Aarnisalo G, Druley R, Beckwith W, Boonen J, Slavich E, Cannon L**

Department of Gastroenterology and Nutrition, Skane University Hospital, Sweden

*** Corresponding Author:** Cannon L, Department of Gastroenterology and Nutrition, Skane University Hospital, Sweden

Citation: Cannon L, Primary Biliary Cholangitis: A Silent Autoimmune Assault on the Liver's Bile Ducts V1(4), 2026

Received date: January 20, 2026**: Accepted date:** January 28, 2026**: Published date:** February 05 ,2026
Keywords: antimitochondrial antibodies, therapeutic interventions, cholestasis, cirrhosis, antimitochondrial antibodies, splenomegaly, lipid abnormalities, liver transplantation

Abstract

Primary Biliary Cholangitis (PBC) is a chronic, progressive autoimmune liver disorder characterized by the gradual destruction of intrahepatic bile ducts. This condition disrupts bile flow, leading to cholestasis, inflammation, fibrosis, and eventually cirrhosis if left untreated. Although often asymptomatic in early stages, PBC can present with fatigue, pruritus, and biochemical abnormalities such as elevated alkaline phosphatase. The disease predominantly affects middle-aged women and is strongly associated with antimitochondrial antibodies. Advances in diagnostic techniques and therapeutic interventions, particularly the use of ursodeoxycholic acid and newer agents, have improved patient outcomes. This article explores the pathogenesis, clinical features, diagnostic strategies, and evolving treatment landscape of PBC, emphasizing the importance of early detection and long-term management.

Introduction

Primary Biliary Cholangitis (PBC) is an autoimmune liver disease that primarily targets the small bile ducts within the liver. Over time, this immune-mediated damage leads to impaired bile secretion, accumulation of toxic substances, and progressive liver injury. Previously known as primary biliary cirrhosis, the condition was renamed to reflect its early-stage pathology, which occurs before cirrhosis develops.

Epidemiology

PBC predominantly affects women, with a female-to-male ratio of approximately9:1. It is most commonly diagnosed between the ages of 40 and 60. Although considered a rare disease, its prevalence has been increasing due to improved awareness and diagnostic capabilities.

Pathogenesis

The exact cause of PBC remains unclear, but it is believed to result from a combination of genetic susceptibility and environmental triggers. The hallmark of the disease is the presence of antimitochondrial antibodies (AMAs), which target components of the mitochondrial enzyme complex in biliary epithelial cells. This leads to chronic inflammation and destruction of bile ducts.

Contributing factors may include:

- Genetic predisposition
- Environmental toxins
- Infections
- Hormonal influences

Clinical Manifestations

Many patients with PBC are asymptomatic at diagnosis, with the condition identified through abnormal liver function tests. When symptoms occur, they may include:

- **Fatigue** – often severe and disproportionate
- **Pruritus (itching)** – especially on palms and soles
- **Jaundice** – in advanced stages

- **Xanthomas and xanthelasmas** – due to lipid abnormalities
- **Hepatomegaly and splenomegaly**

As the disease progresses, complications such as portal hypertension, osteoporosis, and fat-soluble vitamin deficiencies may develop.

Diagnosis

Diagnosis of PBC is typically based on a combination of clinical, biochemical, serological, and histological findings

1. **Liver Function Tests**
   - Elevated alkaline phosphatase (ALP)
   - Mild elevations in transaminases
2. **Serology**
   - Presence of antimitochondrial antibodies (AMAs) in ~90–95% of cases
3. **Imaging**
   - Ultrasound or MRCP to exclude other causes of cholestasis
4. **Liver Biopsy** (if needed)
   - Confirms diagnosis and assesses disease stage

Management and Treatment

The primary goal of treatment is to slow disease progression and manage symptoms.

Pharmacological Therapy

- **Ursodeoxycholic acid (UDCA)**
  First-line treatment; improves bile flow and delays disease progression
- **Obeticholic acid (OCA)**
  Used in patients with inadequate response to UDCA
- **Fibrates** (emerging therapy)
  Show promise in reducing cholestasis

Symptom Management

- Antihistamines or bile acid sequestrants for pruritus
- Vitamin supplementation (A, D, E, K)

Advanced Disease

- Liver transplantation is considered in cases of liver failure or severe complications

Prognosis

With early diagnosis and appropriate treatment many patients can maintain a good quality of life and normal life expectancy. However, untreated or advanced PBC may progress to cirrhosis and liver failure.

Conclusion

Primary Biliary Cholangitis is a chronic autoimmune disease with potentially serious consequences if not managed effectively. Early detection, regular monitoring, and adherence to treatment are crucial in slowing disease progression. Ongoing research continues to improve understanding and expand therapeutic options, offering hope for better patient outcomes in the future

References

1. Nuzzo, F.; Paraboschi, E.M.; Straniero, L.; Pavlova, A.; Duga, S.; Castoldi, E. Identification of a Novel Large Deletion in a Patient with Severe Factor V Deficiency Using an In-House F5 MLPA Assay. Haemophilia 2015, 21, 140–147.
2. Bruning, J.C.; Fenselau, H. Integrative neurocircuits that control metabolism and food intake. Science 2023, 381, eabl7398.
3. Broeders, E.P.; Nascimento, E.B.; Havekes, B.; Brans, B.; Roumans, K.H.; Tailleux, A.; Schaart, G.; Kouach, M.; Charton, J.; Deprez, B.; et al. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. Cell Metab. 2015, 22, 418–426.
4. Wiebe, I.; Baig, Z.; Sothilingam, N. Hemorrhagic cholecystitis from isolated gallbladder injury following blunt abdominal trauma: An unusual case report. Int. J. Surg. Case Rep. 2022, 90, 106680.
5. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 2005, 329, 386–390.
6. Pedrosa, M.; Seyedkazemi, S.; Francque, S.; Sanyal, A.; Rinella, M.; Charlton, M.; Loomba, R.; Ratziu, V.; Kochuparampil, J.; Fischer, L.; et al. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp. Clin. Trials 2020, 88, 105889.
7. Taghavi, S.M.J.; Jaya Kumar, M.; Damodaran Prabha, R.; Puhalla, H.; Sommerville, C. Cystic artery pseudoaneurysm: Current review of aetiology, presentation, and management. Surg. Res. Pract. 2021, 2021, 4492206.

Journal of Innovations in Medical Research and Clinical case Reports (JIMRCR)

DOI:10/JIMRCR/2026/017

.